[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @BiotechYOLO789 BiotechYOLO789 BiotechYOLO789 posts on X about $caba, $roiv, $kytx, upside the most. They currently have XX followers and XX posts still getting attention that total X engagements in the last XX hours. ### Engagements: undefined [#](/creator/twitter::1958183929925844993/interactions)  - X Week XXX -XX% - X Month XXXXX -XX% ### Mentions: undefined [#](/creator/twitter::1958183929925844993/posts_active)  - X Month X -XX% ### Followers: XX [#](/creator/twitter::1958183929925844993/followers)  - X Week XX +35% - X Month XX +85% ### CreatorRank: undefined [#](/creator/twitter::1958183929925844993/influencer_rank)  ### Social Influence [#](/creator/twitter::1958183929925844993/influence) --- **Social topic influence** [$caba](/topic/$caba), [$roiv](/topic/$roiv), [$kytx](/topic/$kytx), [upside](/topic/upside), [$125m](/topic/$125m), [$250sh](/topic/$250sh), [$cabas](/topic/$cabas) **Top assets mentioned** [Roivant Sciences Ltd. Common Shares (ROIV)](/topic/$roiv) ### Top Social Posts [#](/creator/twitter::1958183929925844993/posts) --- Top posts by engagements in the last XX hours "$ROIV Positive P3. Plan to file NDA in 1H2026" [X Link](https://x.com/BiotechYOLO789/status/1968288420482130037) [@BiotechYOLO789](/creator/x/BiotechYOLO789) 2025-09-17T12:18Z XX followers, XXX engagements "$ROIV positive P3 data in dermatomyositis is best-case scenario for $CABA. Brepo efficacy was solid and should be 1L in a terrible disease but leaves significant room for the life-altering improvement of CAR-T in severe refractory patients (of which there will be plenty)" [X Link](https://x.com/BiotechYOLO789/status/1968329291101581790) [@BiotechYOLO789](/creator/x/BiotechYOLO789) 2025-09-17T15:00Z XX followers, XXX engagements "In the meantime $ROIV likely to launch YE26 or early 2027 creating significantly more disease awareness among patients providers and investors and growing the market With $CABA likely to file in early 2027 in DM (and ASyS) this is the perfect narrative to draft off of" [X Link](https://x.com/BiotechYOLO789/status/1968329294469595228) [@BiotechYOLO789](/creator/x/BiotechYOLO789) 2025-09-17T15:00Z XX followers, XXX engagements "@Vic83906204 No reason to raise. They have $125M worth of common warrants at $2.50/sh and why would the ye do something before ACR $CABA sell off makes zero sense especially with $KYTX flat" [X Link](https://x.com/BiotechYOLO789/status/1976703222531399997) [@BiotechYOLO789](/creator/x/BiotechYOLO789) 2025-10-10T17:35Z XX followers, XXX engagements "$CABA $KYTX Biotech investors need to figure out what they want. Makes zero sense for Kyverna to be trading 30%+ higher F/D mkt cap vs. Cabaletta as they have similar cash on the BS. It should be the opposite after $CABAs ESGCT data w/o preconditioning announced yesterday" [X Link](https://x.com/BiotechYOLO789/status/1976717996086444253) [@BiotechYOLO789](/creator/x/BiotechYOLO789) 2025-10-10T18:34Z XX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@BiotechYOLO789 BiotechYOLO789
BiotechYOLO789 posts on X about $caba, $roiv, $kytx, upside the most. They currently have XX followers and XX posts still getting attention that total X engagements in the last XX hours.
Engagements: undefined #
- X Week XXX -XX%
- X Month XXXXX -XX%
Mentions: undefined #
- X Month X -XX%
Followers: XX #
- X Week XX +35%
- X Month XX +85%
CreatorRank: undefined #
Social Influence #
Social topic influence $caba, $roiv, $kytx, upside, $125m, $250sh, $cabas
Top assets mentioned Roivant Sciences Ltd. Common Shares (ROIV)
Top Social Posts #
Top posts by engagements in the last XX hours
"$ROIV Positive P3. Plan to file NDA in 1H2026"
X Link @BiotechYOLO789 2025-09-17T12:18Z XX followers, XXX engagements
"$ROIV positive P3 data in dermatomyositis is best-case scenario for $CABA. Brepo efficacy was solid and should be 1L in a terrible disease but leaves significant room for the life-altering improvement of CAR-T in severe refractory patients (of which there will be plenty)"
X Link @BiotechYOLO789 2025-09-17T15:00Z XX followers, XXX engagements
"In the meantime $ROIV likely to launch YE26 or early 2027 creating significantly more disease awareness among patients providers and investors and growing the market With $CABA likely to file in early 2027 in DM (and ASyS) this is the perfect narrative to draft off of"
X Link @BiotechYOLO789 2025-09-17T15:00Z XX followers, XXX engagements
"@Vic83906204 No reason to raise. They have $125M worth of common warrants at $2.50/sh and why would the ye do something before ACR $CABA sell off makes zero sense especially with $KYTX flat"
X Link @BiotechYOLO789 2025-10-10T17:35Z XX followers, XXX engagements
"$CABA $KYTX Biotech investors need to figure out what they want. Makes zero sense for Kyverna to be trading 30%+ higher F/D mkt cap vs. Cabaletta as they have similar cash on the BS. It should be the opposite after $CABAs ESGCT data w/o preconditioning announced yesterday"
X Link @BiotechYOLO789 2025-10-10T18:34Z XX followers, XXX engagements